Please login to the form below

Not currently logged in
Email:
Password:

skin cancer

This page shows the latest skin cancer news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

As a latecomer to the immunotherapy class, Libtayo first entered the market in 2018 with an approval in advanced cutaneous squamous cell carcinoma, a form of skin cancer. ... In February, Libtayo received US Food and Drug Administration (FDA) approval in

Latest news

More from news
Approximately 19 fully matching, plus 130 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    For example, skin cancer patients who carry a BRAF V600 mutation are more likely to respond to BRAF inhibitors like Roche’s Zelboraf (Vemurafenib) than people without such mutations. ... He also cited an FDA-approved TMB test developed by Foundation

  • Digital health Digital health

    What digital health has delivered to date is amazing. The examples are legion: an application which can differentially diagnose lesions on skin with 20-30 times more accuracy than a doctor ... when it comes to skin cancer, or HealthTap’s Dr AI which

  • Case study: Skin cancer awareness

    Skin cancer is on the increase. It is one of the most common cancers in the 15-24 age group and a significant cause of death. ... Posters and leaflets do not get through to younger people; at this age they feel invincible and believe skin cancer will

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • CytomX appoints Rachel Humphrey chief medical officer CytomX appoints Rachel Humphrey chief medical officer

    Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Keith Nolop joins US cancer biotech from Plexxikon. Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief ... At Plexxikon, he also led the filing of eight

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics